Theseus Pharmaceuticals is passionately committed to outsmarting cancer resistance. The Company is developing best-in-class, pan-variant kinase inhibitors, to shape the future of targeted oncology. Theseus believes truly transformative, targeted oncology therapeutics must inhibit all clinically relevant variants. Led by a team of pioneers in the discovery and development of tyrosine kinase inhibitors (TKIs), the Company's technology can predict how a cancer will mutate, enabling Theseus to target known mutations, stay ahead of future variants, and overcome the demonstrated burden of treatment resistance. For more information, visit www.theseusrx.com.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
04/13/21	$100,000,000	Series B	Adage Capital Management Boxer Capital Farallon Capital Management Foresite Capital Longitude Capital Nextech Ventures Omega Funds OrbiMed Advisors Pontifax Rock Springs Capital T. Rowe Price Associates	undisclosed